Investors in LightPath Technologies (NASDAQ:LPTH) have seen respectable returns of 38% over the past year
Passive investing in index funds can generate returns that roughly match the overall market. But one can do better than...
Source: yahoo.com
Page 22 - Lightpath Technologies News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Lightpath Technologies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Lightpath Technologies Today - Breaking & Trending Today
Recent Research Analysts' Ratings Changes for LightPath Technologies (LPTH)
LightPath Technologies (NASDAQ: LPTH) recently received a number of ratings updates from brokerages and research firms: 7/8/2023 – LightPath Technologies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock. 6/30/2023 – LightPath Technologies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock. 6/30/2023 […]
Source: dailypolitical.com
Recent Research Analysts' Ratings Changes for LightPath Technologies (LPTH)
LightPath Technologies (NASDAQ: LPTH) recently received a number of ratings updates from brokerages and research firms: 7/8/2023 – LightPath Technologies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock. 6/30/2023 – LightPath Technologies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock. 6/30/2023 […]
Source: wkrb13.com
LightPath Technologies: Direct Beneficiary Of China's Germanium Export Restrictions
On July 4, 2023, China announced major export restrictions on gallium and germanium. Click here to find out why this makes me bullish on LPTH stock.
Source: seekingalpha.com
Stock Analysts' New Coverage for July 8th (ACRX, ADXS, AGLE, AINC, AJRD, AMPE, AMS, APDN, ARGO, AWH)
Stock Analysts’ new coverage for Saturday, July 8th: StockNews.com initiated coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX). The firm issued a sell rating on the stock. StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS). The firm issued a sell rating on the stock. StockNews.com assumed coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLE). They issued […]
Source: modernreaders.com